GlassScriptPhysician profile
Matthew T Collins
NPI 1568444339
$1,326.14
in general payments reported to CMS, 2019-2025
24 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $55.17 · 2021: $13.21 · 2022: $65.89 · 2023: $185 · 2024: $191 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $232.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.84 | 2019-2025 | |
| Abiomed | $104.80 | 2023 | Impella |
| Abbvie INC. | $96.94 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Organon LLC | $93.81 | 2023-2025 | Nexplanon |
| Therapeuticsmd, INC. | $83.74 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $82.51 | 2019-2025 | |
| Exeltis, USA INC. | $71.47 | 2019-2025 | Slynd |
| Pfizer INC. | $64.51 | 2019-2025 | |
| Novo Nordisk INC | $62.06 | 2019-2025 | Wegovy |
| Hologic Sales and Service, LLC | $51.44 | 2019-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Ethicon US, LLC | $42.13 | 2022 | |
| Merck Sharp & Dohme LLC | $37.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.60 | 2025 | Jardiance |
| Astellas Pharma US INC | $24.43 | 2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.02 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $16.01 | 2019 | |
| Laborie Medical Technologies Corp. | $15.58 | 2025 | |
| Biogen, INC. | $15.57 | 2025 | Zurzuvae |
| Wound Management Technologies, INC | $13.37 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.66 | 2019 | |
| Avion Pharmaceuticals | $12.42 | 2019 | |
| Mission Pharmacal Company | $11.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.